151
Participants
Start Date
June 27, 2023
Primary Completion Date
October 28, 2024
Study Completion Date
October 28, 2024
Chondroitin sulfate
Chondroitin sulfate (CS) is a natural biomacromolecule belonging to the class of glycosaminoglycans and is an unbranched complex polysaccharide consisting of a repeating disaccharide structure of glucuronic acid and N-acetyl-D-glucosamine \[18\]. It is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans. Oral bioavailability of CS has been demonstrated \[19\], and its use for the treatment of OA has been established in animal models \[20\], as well as in clinical trials \[21, 22\]. CS, is available as a pharmaceutical grade drug (Structum®), meaning that the product is manufactured under Good Manufacturing Practices (GMP) conditions, and is in excess of 99% purity with no binders, fillers, excipients, dyes, or unknown substances. According to the Instructions for Use (IFU), the recommended posology for Structum® is 500 mg twice daily.
Maciej Dołżyński, Bialystok
Piotr Ligocki, Bydgoszcz
Elżbieta Pietrus- Dunaszewska, Katowice
Bartlomiej Szpyra, Krakow
Alina Wołkowicz Mruk, Krakow
Andrzej Majer, Kujakowice Gorn
Agnieska WIAK, Lubartów
Wojciech Larczyński, Nowy Dwór Gdański
Sławomir Panek, Olesno
Marcin Milchert, Szczecin
Wojciech Roczniak, Ustrzyki Dolne
Zdzisław Derleta, Warsaw
Michał Straburzyński, Zielona Góra
Mariusz Borowiecki, Zielona Góra
Viktor Kostiuk, Żagań
Pierre Fabre Medicament
INDUSTRY